Navigation Links
Connect the Quantum Dots

A new study, published today in the current issue of the Proceedings of the National Academy of Sciences has significant implications for the design of disease markers and the development of chemoreceptors used in human biomedical research. The groundbreaking study, entitled, "A Mechanism to Signal Receptor-Substrate Interactions with Luminescent Quantum Dots", demonstrates that quantum dots can one day replace conventional organic dyes in biomedical applications.

By using the unique photophysical properties of quantum dots, researchers Drs. Francisco Raymo, Ibrahim Yildiz, and Massimilliano Tomasulo were able to identify operating principles to probe molecular recognition events with luminescence measurements. These findings demonstrate that mechanisms based on photoinduced electron transfer can be exploited to transduce a recognition event into a significant change in the luminescence of a quantum dot. This research proves this important fundamental principle and lay the necessary groundwork for researchers to further improve its sensitivity, stability and reproducibility for biomedical applications.

"Our method has a long-term impact on biomedical diagnostic applications which currently rely on the fluorescence of organic dyes," says Francisco Raymo, Ph.D., associate professor of chemistry in the University of Miami's College of Arts and Sciences. "For example, our strategy can be designed to signal specific disease markers in biological samples thus replacing conventional organic dyes in a diversity of imaging and sensing applications."

Fluorescence microscopy and spectroscopy have become invaluable analytical tools in biomedical research but rely on the fluorescence of organic dyes which have limited luminescent properties. Quantum dots have superior photophysical properties and will presumably replace conventional organic dyes in biomedical applications. These findings will stimulate the use of quantum dots in the biomedical resea rch and development of disease markers and chemosensors.

"On its own this research paper is very significant and ahead of its time in the field of nanotechnology," says Alexey Titov, Licensing Manager for the University of Miami's Office of Technology Transfer. "However, it also has commercial applications which are a truly outstanding and rare combination."

Two patent applications have been filed by University of Miami Office of Technology Transfer on behalf of Dr. Raymo and colleagues for these inventions and the university is in the process of finding an industrial partner capable of commercializing these inventions.

Quantum dots, one of the smallest nanoscience research tools, range from 2 to 10 nanometers in diameter; nearly 3 million quantum dots would be needed to fit within the width of a thumb. By virtue of their distinct colors, quantum dots have quickly found their way into homes in many electronic lasers including the new PlayStation 3 and high-definition DVD players. Nanotechnology, the understanding and control of matter at dimensions of roughly 1 to 100 nanometers, is valuable research since matter at the nanoscale has unique properties that enable novel applications. Medical researchers work at the nano-scales can develop new drug delivery methods, therapeutics and pharmaceuticals.


'"/>

Source:University of Miami Rosenstiel School of Marine & Atmospheric Science


Related biology news :

1. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
2. Quantum dots provide a faster, more sensitive method for detecting respiratory viral infections
3. Quantum dots reviewed -- Could these nanoparticles hold the cure to cancer?
4. First Quantum Grant to fund stem cell repair of damage from stroke
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017 ... enhancing user experience and security for consumer electronics, ... next-generation payment processing systems and cybersecurity solutions, today ... banks, enterprises and financial institutions worldwide to bolster ... of the end-to-end secure user authentication platforms they ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)... 16, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, today announced it ... and entered into a $5 million credit facility ... use the capital for general corporate purposes to ... the treatment of serious diseases treated by dermatologists. ...
Breaking Biology Technology: